Therapeutic Advances in Gastroenterology (@tagastroenterol) 's Twitter Profile
Therapeutic Advances in Gastroenterology

@tagastroenterol

A gold open access peer-reviewed journal publishing high-quality articles across all areas of gastroenterology, hepatology and related disciplines. IF=3.9

ID: 1306361558394712064

linkhttp://tag.sagepub.com calendar_today16-09-2020 22:38:34

564 Tweet

1,1K Followers

1,1K Following

Therapeutic Advances in Gastroenterology (@tagastroenterol) 's Twitter Profile Photo

🆘 In 6 patients with corticosteroid + infliximab-refractory acute severe UC, JAK inhibitors (upadacitinib/tofacitinib) led to clinical response in 4/6 within 72h. All responders were colectomy-free and in steroid-free remission by day 90. Read here: journals.sagepub.com/doi/epdf/10.11…

🆘 In 6 patients with corticosteroid + infliximab-refractory acute severe UC, JAK inhibitors (upadacitinib/tofacitinib) led to clinical response in 4/6 within 72h. All responders were colectomy-free and in steroid-free remission by day 90. 

Read here: journals.sagepub.com/doi/epdf/10.11…
Jonny Blackwell (@jonnyblackwell) 's Twitter Profile Photo

I think this is important but must only be done fully explaining to the patient that it is an unevidenced intervention & there may be considerable risks.

Therapeutic Advances in Gastroenterology (@tagastroenterol) 's Twitter Profile Photo

🚨 For massive rectal GISTs >5cm, transanal endoscopic resection (taLR) matched radical surgery on 5-yr DFS (94.1% vs 100%, p=0.405), while reducing OR time, hospital stay & preserving anal function. A QoL-preserving alternative. Read here: journals.sagepub.com/doi/epdf/10.11…

🚨 For massive rectal GISTs >5cm, transanal endoscopic resection (taLR) matched radical surgery on 5-yr DFS (94.1% vs 100%, p=0.405), while reducing OR time, hospital stay & preserving anal function. A QoL-preserving alternative. 

Read here: journals.sagepub.com/doi/epdf/10.11…
Therapeutic Advances in Gastroenterology (@tagastroenterol) 's Twitter Profile Photo

In MASLD and MetALD, current smoking significantly worsened survival and increased risks of cirrhosis, CVD, and liver-related mortality. Never smokers had lowest risks across most outcomes. 📊 Supports strong cessation strategies in liver disease care. doi.org/10.1177/175628…

In MASLD and MetALD, current smoking significantly worsened survival and increased risks of cirrhosis, CVD, and liver-related mortality. Never smokers had lowest risks across most outcomes.
📊 Supports strong cessation strategies in liver disease care.
 
doi.org/10.1177/175628…
Therapeutic Advances in Gastroenterology (@tagastroenterol) 's Twitter Profile Photo

Anti-reflux mucosectomy significantly improved LES pressure, Hill’s grade, and GERD-related symptom scores vs argon plasma coagulation in Barrett’s esophagus. A stronger reflux barrier with lower lesion residue—supporting ARMS as a dual-target strategy. doi.org/10.1177/175628…

Anti-reflux mucosectomy significantly improved LES pressure, Hill’s grade, and GERD-related symptom scores vs argon plasma coagulation in Barrett’s esophagus.
A stronger reflux barrier with lower lesion residue—supporting ARMS as a dual-target strategy.
 
doi.org/10.1177/175628…
Therapeutic Advances in Gastroenterology (@tagastroenterol) 's Twitter Profile Photo

Smoking, MASLD, cerebrovascular disease, H. pylori persistence, multiple lesions & severe atrophic gastritis all linked to metachronous gastric cancer post-curative ESD. A nomogram showed strong predictive accuracy (C-index up to 0.845). doi.org/10.1177/175628…

Smoking, MASLD, cerebrovascular disease, H. pylori persistence, multiple lesions & severe atrophic gastritis all linked to metachronous gastric cancer post-curative ESD.
A nomogram showed strong predictive accuracy (C-index up to 0.845).
 
doi.org/10.1177/175628…
Therapeutic Advances in Gastroenterology (@tagastroenterol) 's Twitter Profile Photo

In unresectable perihilar cholangiocarcinoma, endoscopic therapy goes beyond biliary drainage. ERCP-based approaches + adjuncts like RFA, PDT & EUS methods offer therapeutic promise where surgery isn’t an option. doi.org/10.1177/175628…

In unresectable perihilar cholangiocarcinoma, endoscopic therapy goes beyond biliary drainage.
ERCP-based approaches + adjuncts like RFA, PDT & EUS methods offer therapeutic promise where surgery isn’t an option.

doi.org/10.1177/175628…
Therapeutic Advances in Gastroenterology (@tagastroenterol) 's Twitter Profile Photo

🧠 In 1344 non-sedated EGD patients, a pre-procedural anxiety score >36 predicted higher odds of incomplete or poor-quality exams (AUC=0.720). Each 1-point increase in STAI-I raised failure odds by 3.8%. Routine anxiety screening could improve outcomes 🔗 journals.sagepub.com/doi/epdf/10.11…

🧠 In 1344 non-sedated EGD patients, a pre-procedural anxiety score >36 predicted higher odds of incomplete or poor-quality exams (AUC=0.720).
Each 1-point increase in STAI-I raised failure odds by 3.8%.
Routine anxiety screening could improve outcomes

🔗 journals.sagepub.com/doi/epdf/10.11…
Therapeutic Advances in Gastroenterology (@tagastroenterol) 's Twitter Profile Photo

🩸 A 29-expert Delphi panel reached consensus on 36 statements for managing delayed post-polypectomy bleeding. Key recommendations: risk stratification to reduce unnecessary colonoscopies, and guidance for antithrombotic and hemostatic management 🔗 journals.sagepub.com/doi/epdf/10.11…

🩸 A 29-expert Delphi panel reached consensus on 36 statements for managing delayed post-polypectomy bleeding.

Key recommendations: risk stratification to reduce unnecessary colonoscopies, and guidance for antithrombotic and hemostatic management

🔗 journals.sagepub.com/doi/epdf/10.11…
Therapeutic Advances in Gastroenterology (@tagastroenterol) 's Twitter Profile Photo

In the phase IIIb CDI-SCOPE trial, fecal microbiota, live-jslm (REBYOTA®) delivered via colonoscopy prevented CDI recurrence in 95.1% of patients over 8 weeks. Only 9.8% experienced mild, RBL-related TEAEs. Safe, practical, and effective. 🔗 journals.sagepub.com/doi/epdf/10.11…

In the phase IIIb CDI-SCOPE trial, fecal microbiota, live-jslm (REBYOTA®) delivered via colonoscopy prevented CDI recurrence in 95.1% of patients over 8 weeks.
Only 9.8% experienced mild, RBL-related TEAEs.
Safe, practical, and effective.

🔗 journals.sagepub.com/doi/epdf/10.11…
Therapeutic Advances in Gastroenterology (@tagastroenterol) 's Twitter Profile Photo

In a 240-patient cohort, fecal microbiota transplant for recurrent C. difficile infection failed in 24.6% of cases (18.3% recurrence, 7.1% death within 1 year). Older age, multiple prior episodes, and diabetes were significantly associated with failure. journals.sagepub.com/doi/epdf/10.11…

In a 240-patient cohort, fecal microbiota transplant for recurrent C. difficile infection failed in 24.6% of cases (18.3% recurrence, 7.1% death within 1 year). Older age, multiple prior episodes, and diabetes were significantly associated with failure.

journals.sagepub.com/doi/epdf/10.11…